'Repair Teeth With NovaMin It is now possible to repair teeth using NovaMin. NovaMin is a white, tasteless powder developed and patented by NovaMin Technology, Inc. Originally, it was developed to help repair the broken bones of battle wounded soldiers. In the 1990s, NovaMin was first used by scientist as a treatment for sensitive teeth. Later on, they found that NovaMin would release certain ions that help remineralize teeth.
Today, it is used in dental care products for the remineralization of teeth. It contains an active ingredient called calcium sodium phosphosilicate, consisting of silica, ionic calcium, phosporus and sodium. These ions are necessary for bone and tooth mineralization. In May 2010, the rights of Novamin were bought over by GlaxoSmithKline for US$135 million.
The underlying layer of the tooth, called the dentine, is a porous layer with many tiny channels running through it to the nerve in the centre. The dentine is protected by a hard enamel layer. When dentine is exposed, the tooth becomes sensitive.
GlaxoSmithKline's product, Sensodyne provides relief for sensitive teeth. With the acquisition of NovaMin, they have now produce a breakthrough formulation with the new Sensodyne Repair & Protect, which is the first fluoride toothpaste to contain the patented NovaMin technology.
When NovaMin is exposed to water or saliva in the mouth, they will release calcium and phosphate ions, which then forms a mineral layer over exposed dentine. This mineral layer is chemically and structurally the same as the tooth mineral. With twice a day brushing, it helps to continuously repair and protect the tooth from further damage and at the same time repairs lesions that cause tooth sensitivity. Thus NovaMin is today the most powerful tooth sensitivity relief.
NovaMin has been clinically proven to show the following benefits :
Anti-microbial and anti-inflammatory benefits Noticeable reduction of tooth sensitivity Remineralization of tooth Prevents the development of dental caries Reduction of gingivitis Noticeable tooth whitening
Dental products which currently using NovaMin includes the following :
Sensodyne NUPRO Prophylaxis Paste with NovaMin, used by dentists in professional teeth cleaning, stain removal and relief of sensitivity. Sensodyne NUPRO Professional Toothpaste with NovaMin for use at home. Sensodyne Repair & Protect DenShield Dr. Collins Restore Toothpaste Nanosensitive hca SensiShield SootheRx Burt's Bees Natural Toothpaste SHY-NM Vantej Odontis-Rx
While some products are sold only through dental professionals, most of the products are sold in stores or through the Internet. A number of the products are sold in European Union, some in USA and Canada and one or two brands can be found in India and Brazil.'
The point of reiterating this article is to demonstrate that GSK's Novamin is already incorporated in their current pipeline of OTC oral care products including Sensodyne.
A potential new product with a targeted OBJ FIM applicator IMO would in effect be a new and more effective means of concentrating the mechanics of this BLOCKBUSTER compound.
IMO this would not be in direct competition with the likes of Sensodyne but rather COMPLIMENT one of their already BLOCKBUSTER OTC Oral Healthcare products by using a 'state-of-the-art' new means for targeted delivery.
In my mind there is little doubt that the 'key oral health ingredient' that GSK & OBJ have been testing is in fact Novamin as per OBJ's recent Sharholder Upadte below:
'An ongoing relationship with GSK (UK) and OBJ’s own internal development programs in the Oral Health sector advanced with the completion of successful OBJ sponsored ex-vivo studies showing enhanced delivery of key oral health ingredients used in the treatment of teeth hypersensitivity (sensitive teeth) and tooth demineralization (re-hardening).The studies undertaken by the independent Modus Laboratories of the UK demonstrated statistically significant increases in the delivery of key compounds into the tooth enamel in as little as two minutes using a toothbrush-styled applicator incorporating OBJ’s FIM technology. This is a very exciting and technically challenging area with opportunities for the Company’s technologies.'
For some on this forum to suggest that GSK is in the business of 'planned obsolescence' is non-sensical & ludacris!
A BLOCKBUSTER is a BLOCKBUSTER in the eyes of one of the World's largest Pharmaceutical companies! Each product with the Novamin compound will have it's own market share & it's pretty obvious that GSK are already aware of this. It's what GSK do and very well for that matter!
This is just one of many collaborations that OBJ's management find 'exciting' & I for one share their sentiment!
And for anyone who doesn't feel that GSK is serious about the future of their innovative pipeline, have a read of the article below taken from their Aussie website 15/08/2012:
'15 Aug 2012 - GlaxoSmithKline reaches agreement to divest majority of Classic Brands in Australia for £172m GlaxoSmithKline plc (GSK) today announced that it has reached agreement to divest the majority of its Classic Brands (25 non-promoted and genericised products) in Australia to Aspen Global Incorporated (Aspen) for approximately £172 million in cash.
The divested brands include Valtrex, Lamictal, Timentin, Amoxil and Aropax and generated total sales of approximately £83 million in 2011 and approximately £31m in the first half of 2012. Revenues for these products have gradually declined over recent years due to local market price reductions and generic competition. It is expected the divestment will complete in Q4 2012, subject to regulatory approvals.
The net cash proceeds from the transaction are expected to be approximately £155 million.
Net profit on this disposal in 2012 (after deducting transaction costs and a profit deferral of approximately £31 million pre-tax arising because Aspen is an associate of GSK) is estimated to be approximately £131 million (pre-tax), £121 million (post-tax) and will be recorded as a non-core item.
GSK Australia’s future growth will come from patent protected brands and new products in its pipeline. The Australian Government’s mandatory 16% price cuts on medicines when they are genericised as well as further annual price cuts based on competitive discounting to pharmacies are likely to continue. This has made the continued distribution of non-promoted and genericised products from GSK Australia Pharmaceuticals unsuitable for planned future growth.
General Manager Pharmaceuticals GlaxoSmithKline Australia, Geoff McDonald said “Our pipeline of new medicines has the potential to transform GSK’s future and as such the divestment of these brands allows us to focus more on bringing these new medicines to Australian patients.”
As with the divestment of its non-core over-the-counter (OTC) brands earlier in 2012, today’s announcement is an example of GSK’s commitment to realise value and enhance returns to shareholders through the sale of low growth or non-core businesses and to focus on priority brands, products and pipeline opportunities that have long term growth potential.'
OBJ Price at posting:
1.3¢ Sentiment: LT Buy Disclosure: Held
(20min delay)